34th Innovation in Postmenopausal Osteoporosis: A Therapeutic Breakthrough - a satellite symposium, European Symposium on Calcified Tissues location:Copenhagen, Denmark date:5-9 May 2007 33rd European Symposium on Calcified Tissues location:Prague, Czech Republic date:10-14 May 2006
In clinical trials, the bisphosphonates risedronate and alendronate have each been shown to reduce the risk of vertebral and nonvertebral fractures as early as 6 months (risedronate) and 12 months (alendronate). In contrast to risedronate and alendronate, ibandronate only reduces the risk of vertebral fractures, with no evidence for its efficacy in hip and nonvertebral fracture reduction. The antifracture efficacy of different bisphosphonates must rely on fracture data since bone mineral density measurements and changes in bone turnover markers appear to have no strict linear correlation with fracture risk reductions. The antifracture efficacy of different bisphosphonates ideally should be compared via head-to-head comparisons in fracture endpoint trials. (C) 2007 Elsevier Inc. All rights reserved.